Recent Publications by SUGEN: |
Effect of Terminalia arjuna extract on adriamycin-induced DNA damage.
The effect of a bark extract of Terminalia arjuna (TAE) was studied on the... | 19th December, 2008
| Division of Cancer Biology, Sugen Life Sciences, Tirupati, 517505, AP,
| Phytother Res. 2008 Sep;22(9):1188-94.
DOI Direct Link |
High-performance liquid chromatographic method for determination of reversible isomers of SU5416.
SU5416 shows light-induced reversible geometric isomerism. A simple,... | 29th June, 2006
| Formulations Research, SUGEN Inc., 230 S. Grand Avenue, South San
| J Chromatogr A. 2006 Mar 31;1110(1-2):73-80. Epub 2006 Feb 10.
DOI Direct Link |
Simultaneous determination of Z-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone (SU5416) and its interconvertible geometric isomer (SU5886) in rat plasma by LC/MS/MS.
Z-3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-2-indolinone (SU5416) is a... | 23rd May, 2006
| Department of Bioanalysis and Phamarcokinetcs, Sugen, 230 E. Grand Ave.,
| J Pharm Biomed Anal. 2005 Jul 1;38(3):479-86. Epub 2005 Mar 2.
DOI Direct Link |
PAK4 mediates morphological changes through the regulation of GEF-H1.
Precise spatial and temporal regulation of Rho GTPases is required in... | 20th September, 2005
| SUGEN Incorporated, 230 East Grand Avenue, South San Francisco, CA 94080,
| J Cell Sci. 2005 May 1;118(Pt 9):1861-72. Epub 2005 Apr 12.
DOI Direct Link |
Transcriptional-based screens for pathway-specific, high-throughput target discovery in endothelial cells.
With the sequence of the human genome at hand, target discovery strategies... | 13th May, 2005
| SUGEN, Inc.,
| J Biomol Screen. 2004 Dec;9(8):704-11.
DOI Direct Link |
Troglitazone induces a rapid drop of mitochondrial membrane potential in liver HepG2 cells.
Troglitazone, a thiazolidinedione containing compound, was widely used to... | 11th February, 2005
| Drug Discovery, SUGEN, Inc., 230 East Grand Avenue, South San Francisco,
| Toxicol Lett. 2005 Jan 15;155(1):41-50.
DOI Direct Link |
Simultaneous determination of Z-SU5416 and its interconvertible geometric E-isomer in rat plasma by LC/MS/MS.
SU5416 is a selective inhibitor of vascular endothelial growth factor... | 28th December, 2004
| Department of Bioanalysis, Metabolism and Phamacokinetics, SUGEN Inc., 230
| J Pharm Biomed Anal. 2004 May 28;35(3):513-22.
DOI Direct Link |
An automated image capture and quantitation approach to identify proteins affecting tumor cell proliferation.
To facilitate the characterization of proteins that negatively regulate... | 5th November, 2004
| Target Discovery Department, Sugen, Inc. (A Subsidiary of Pfizer), South
| J Biomol Screen. 2004 Apr;9(3):216-22.
DOI Direct Link |
The mouse kinome: discovery and comparative genomics of all mouse protein kinases.
We have determined the full protein kinase (PK) complement (kinome) of... | 30th September, 2004
| SUGEN, Incorporated, 230 East Grand Avenue, South San Francisco, CA 94025,
| Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11707-12. Epub 2004 Aug 2.
DOI Direct Link |
The oxidative mechanism of action of ortho-quinone inhibitors of protein-tyrosine phosphatase alpha is mediated by hydrogen peroxide.
Here, we report the identification and characterization of five... | 8th September, 2004
| Drug Discovery, SUGEN Inc., 230 East Grand Avenue, South San Francisco, CA
| Arch Biochem Biophys. 2004 Sep 1;429(1):30-41.
DOI Direct Link |
Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
Acute myeloid leukemia (AML) is associated with dysregulated hematopoietic... | 23rd July, 2004
| Sugen Inc., South San Francisco, CA, USA.
| Leuk Res. 2004 Jul;28(7):679-89.
DOI Direct Link |
Powder-in-bottle formulation of SU011248. Enabling rapid progression into human clinical trials.
SU011248 is an oral, multitargeted receptor tyrosine kinase inhibitor... | 15th June, 2004
| Sugen Inc. (a Pharmacia Company), S. San Francisco, California, USA.
| Drug Dev Ind Pharm. 2004 Jan;30(1):19-25.
DOI Direct Link |
Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor.
Biomarkers that indicate biological activity and/or efficacy are a... | 19th March, 2004
| Department of Preclinical Research and Exploratory Development, SUGEN,
| Oncogene. 2004 Feb 26;23(8):1618-26.
DOI Direct Link |
